Vivos Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
A group of investment entities and their manager have disclosed a significant beneficial ownership stake in Vivos Therapeutics, Inc., totaling 19.9% as of July 15, 2026.
NASDAQ
Vivos Therapeutics, Inc. (VVOS) has filed a Schedule 13D detailing significant shareholdings and a recent private placement involving V-CO Investors LLC and its affiliates.
NASDAQ
SCHEDULE 13D: Investment Group Acquires Significant Stake in Vivos Therapeutics, Citing Strategic Investment and Funding for Acquisition
A group of investors led by SP Manager LLC and Michael C. Skaff has acquired a 19.9% beneficial ownership stake in Vivos Therapeutics, Inc. through a private placement, providing capital for the company's acquisition of The Sleep Center of Nevada and general working capital.